Literature DB >> 18502655

Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.

Hua Zhang1, Qin Li, Rona K Graham, Elizabeth Slow, Michael R Hayden, Ilya Bezprozvanny.   

Abstract

Huntington's disease (HD) is caused by a progressive loss of striatal medium spiny neurons (MSN). The molecular trigger of HD is a polyglutamine expansion in the Huntingtin protein (Htt). The mutant Htt protein forms insoluble nuclear aggregates which have been proposed to play a key role in causing neuronal cell death in HD. Other lines of investigation suggest that expression of mutant Htt facilitates activity of the NR2B subtype of NMDA receptors and the type 1 inositol 1,4,5-trisphosphate receptors (InsP(3)R1), and that disturbed calcium (Ca(2+)) signaling causes apoptosis of MSNs in HD. The YAC128 transgenic HD mouse model expresses the full-length human Htt protein with 120Q CAG repeat expansion and displays an age-dependent loss of striatal neurons as seen in human HD brain. In contrast, the shortstop mice express an amino-terminal fragment of the mutant Htt protein (exons 1 and 2) and display no behavioral abnormalities or striatal neurodegeneration despite widespread formation of neuronal inclusions. Here we compared Ca(2+) signals in primary MSN neuronal cultures derived from YAC128 and shortstop mice to their wild-type non-transgenic littermates. Repetitive application of glutamate results in supranormal Ca(2+) responses in YAC128 MSNs, but not in shortstop MSNs. In addition, while currents mediated by the NR2B subtype of NMDA receptors were increased in YAC128 MSNs, currents in SS MSNs were found to be similar to WT. Furthermore, YAC128 MSNs were sensitized to glutamate-induced apoptosis. Consistent with these findings, we found that application of glutamate induced rapid loss of mitochondrial membrane potential in YAC128 MSNs. In contrast, SS MSNs do not show increased cell death postglutamate treatment nor accelerated loss of mitochondrial membrane potential following glutamate stimulation. Glutamate-induced loss of mitochondrial membrane potential in YAC128 MSNs could be prevented by inhibitors of NR2B NMDA receptors and mGluR1/5 receptors. Our results are consistent with the hypothesis that disturbed neuronal Ca(2+) signaling plays a significant role in the degeneration of MSN containing full-length mutant Htt(exp). Furthermore, the results obtained with neurons from shortstop mice provide additional evidence that not all fragments of mutant Htt(exp) are toxic to neurons.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18502655      PMCID: PMC2528878          DOI: 10.1016/j.nbd.2008.03.010

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  60 in total

Review 1.  Mouse models of Huntington's disease.

Authors:  Liliana B Menalled; Marie-Françoise Chesselet
Journal:  Trends Pharmacol Sci       Date:  2002-01       Impact factor: 14.819

2.  Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95.

Authors:  Y Sun; A Savanenin; P H Reddy; Y F Liu
Journal:  J Biol Chem       Date:  2001-04-23       Impact factor: 5.157

3.  Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.

Authors:  Robert J Ferrante; Ole A Andreassen; Alpaslan Dedeoglu; Kimberly L Ferrante; Bruce G Jenkins; Steven M Hersch; M Flint Beal
Journal:  J Neurosci       Date:  2002-03-01       Impact factor: 6.167

4.  Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin.

Authors:  Rona K Graham; Yu Deng; Elizabeth J Slow; Brendan Haigh; Nagat Bissada; Ge Lu; Jacqueline Pearson; Jacqueline Shehadeh; Lisa Bertram; Zoe Murphy; Simon C Warby; Crystal N Doty; Sophie Roy; Cheryl L Wellington; Blair R Leavitt; Lynn A Raymond; Donald W Nicholson; Michael R Hayden
Journal:  Cell       Date:  2006-06-16       Impact factor: 41.582

5.  Inhibition of polyglutamine aggregation in R6/2 HD brain slices-complex dose-response profiles.

Authors:  D L Smith; R Portier; B Woodman; E Hockly; A Mahal; W E Klunk; X J Li; E Wanker; K D Murray; G P Bates
Journal:  Neurobiol Dis       Date:  2001-12       Impact factor: 5.996

6.  NMDA receptor function in mouse models of Huntington disease.

Authors:  C Cepeda; M A Ariano; C R Calvert; J Flores-Hernández; S H Chandler; B R Leavitt; M R Hayden; M S Levine
Journal:  J Neurosci Res       Date:  2001-11-15       Impact factor: 4.164

7.  Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene.

Authors:  O Hansson; E Guatteo; N B Mercuri; G Bernardi; X J Li; R F Castilho; P Brundin
Journal:  Eur J Neurosci       Date:  2001-11       Impact factor: 3.386

8.  Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice.

Authors:  G A MacGibbon; L C Hamilton; S F Crocker; W J Costain; K M Murphy; H A Robertson; E M Denovan-Wright
Journal:  J Neurosci Res       Date:  2002-02-01       Impact factor: 4.164

9.  Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease.

Authors:  Melinda M Zeron; Oskar Hansson; Nansheng Chen; Cheryl L Wellington; Blair R Leavitt; Patrik Brundin; Michael R Hayden; Lynn A Raymond
Journal:  Neuron       Date:  2002-03-14       Impact factor: 17.173

Review 10.  Lessons from animal models of Huntington's disease.

Authors:  David C Rubinsztein
Journal:  Trends Genet       Date:  2002-04       Impact factor: 11.639

View more
  48 in total

1.  Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment.

Authors:  Juliette Gafni; Theodora Papanikolaou; Francesco Degiacomo; Jennifer Holcomb; Sylvia Chen; Liliana Menalled; Andrea Kudwa; Jon Fitzpatrick; Sam Miller; Sylvie Ramboz; Pasi I Tuunanen; Kimmo K Lehtimäki; X William Yang; Larry Park; Seung Kwak; David Howland; Hyunsun Park; Lisa M Ellerby
Journal:  J Neurosci       Date:  2012-05-30       Impact factor: 6.167

Review 2.  Mutant Huntingtin and Elusive Defects in Oxidative Metabolism and Mitochondrial Calcium Handling.

Authors:  Nickolay Brustovetsky
Journal:  Mol Neurobiol       Date:  2015-05-05       Impact factor: 5.590

Review 3.  The excitatory neurotransmitter glutamate stimulates DNA repair to increase neuronal resiliency.

Authors:  Jenq-Lin Yang; Peter Sykora; David M Wilson; Mark P Mattson; Vilhelm A Bohr
Journal:  Mech Ageing Dev       Date:  2011-06-25       Impact factor: 5.432

4.  Neuronal store-operated calcium entry pathway as a novel therapeutic target for Huntington's disease treatment.

Authors:  Jun Wu; Hsin-Pei Shih; Vladimir Vigont; Lori Hrdlicka; Len Diggins; Carol Singh; Matt Mahoney; Richard Chesworth; Gideon Shapiro; Olga Zimina; Xuesong Chen; Qingqing Wu; Lyubov Glushankova; Michael Ahlijanian; Gerhard Koenig; Galina N Mozhayeva; Elena Kaznacheyeva; Ilya Bezprozvanny
Journal:  Chem Biol       Date:  2011-06-24

5.  HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity.

Authors:  Virginia B Mattis; Colton Tom; Sergey Akimov; Jasmine Saeedian; Michael E Østergaard; Amber L Southwell; Crystal N Doty; Loren Ornelas; Anais Sahabian; Lindsay Lenaeus; Berhan Mandefro; Dhruv Sareen; Jamshid Arjomand; Michael R Hayden; Christopher A Ross; Clive N Svendsen
Journal:  Hum Mol Genet       Date:  2015-03-03       Impact factor: 6.150

6.  The involvement of the mGluR5-mediated JNK signaling pathway in rats with diabetic retinopathy.

Authors:  Yan-Ni Zhu; Guo-Jin Zuo; Qi Wang; Xiao-Ming Chen; Jin-Kui Cheng; Shu Zhang
Journal:  Int Ophthalmol       Date:  2019-01-03       Impact factor: 2.031

7.  Calcium signaling and neurodegenerative diseases.

Authors:  Ilya Bezprozvanny
Journal:  Trends Mol Med       Date:  2009-02-21       Impact factor: 11.951

8.  Dysregulation of mitochondrial calcium signaling and superoxide flashes cause mitochondrial genomic DNA damage in Huntington disease.

Authors:  Jiu-Qiang Wang; Qian Chen; Xianhua Wang; Qiao-Chu Wang; Yun Wang; He-Ping Cheng; Caixia Guo; Qinmiao Sun; Quan Chen; Tie-Shan Tang
Journal:  J Biol Chem       Date:  2012-12-17       Impact factor: 5.157

9.  Ginsenosides protect striatal neurons in a cellular model of Huntington's disease.

Authors:  Jun Wu; Hye Kyoung Jeong; Sarah Elizabeth Bulin; Sung Won Kwon; Jeong Hill Park; Ilya Bezprozvanny
Journal:  J Neurosci Res       Date:  2009-06       Impact factor: 4.164

10.  Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2.

Authors:  Jing Liu; Tie-Shan Tang; Huiping Tu; Omar Nelson; Emily Herndon; Duong P Huynh; Stefan M Pulst; Ilya Bezprozvanny
Journal:  J Neurosci       Date:  2009-07-22       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.